Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Safety And Pharmacokinetic Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Metastatic Hormone Refractory Prostate Cancer (HRPC)

NCT00137436 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00137436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00137436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Safety And Pharmacokinetic Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Metastatic Hormone Refractory Prostate Cancer (HRPC)
Lead sponsor
Pfizer
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2005
Completion date
March 31, 2010
Enrollment
93 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic neoplasms